MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

9475	Companies
185442	Keywords
117781	Articles
99296	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 11/20/2024 at 13:44, 1 year ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
MIRA Pharmaceuticals progresses towards clinical-stage status with Phase I/IIa trial announcement on Ketamir-2, a novel oral ketamine analog, for pain management. CHDR's PainCart technology leveraged

Pain Management MIRA Pharmaceuticals Ketamir-2 Clinical-stage Company Phase I/IIa Trial
BRIEF

published on 10/28/2024 at 12:35, 1 year 1 month ago

MIRA Pharmaceuticals Reveals Promising Preclinical Results for Ketamir-2

Preclinical Results MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain FDA Designation
BRIEF

published on 10/28/2024 at 12:35, 1 year 1 month ago

MIRA Pharmaceuticals révèle des résultats précliniques prometteurs pour le kétamir-2

Résultats Précliniques Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique Désignation De La FDA
PRESS RELEASE

published on 10/28/2024 at 12:30, 1 year 1 month ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
MIRA Pharmaceuticals announces promising preclinical results for Ketamir-2, a potential breakthrough therapy surpassing current treatments. Study shows 60% greater efficacy than gabapentin in reducing chemotherapy-induced pain, to be presented at Pain Therapeutics Summit

Pain Management Preclinical Results MIRA Pharmaceuticals Ketamir-2 Breakthrough Therapy
BRIEF

published on 10/21/2024 at 13:35, 1 year 1 month ago

MIRA Pharmaceuticals Introduces Ketamir-2 as a Promising Pain Relief Alternative

Preclinical Study MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Gabapentin And Pregabalin
BRIEF

published on 10/21/2024 at 13:35, 1 year 1 month ago

MIRA Pharmaceuticals présente le kétamir-2 comme une alternative prometteuse au traitement de la douleur

Étude Préclinique Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique Gabapentine Et Prégabaline
PRESS RELEASE

published on 10/21/2024 at 13:30, 1 year 1 month ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIRA Pharmaceuticals, Inc. announces promising results for novel oral ketamine analog Ketamir-2 in providing superior pain relief compared to current treatments. Preparing for Phase 1 clinical trials and exploring potential in PTSD

Clinical Trials PTSD MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 09/27/2024 at 13:35, 1 year 2 months ago

MIRA Pharmaceuticals Reveals New Data on Ketamir-2 at Annual Pain Therapeutics Summit

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pain Therapeutics Summit
BRIEF

published on 09/27/2024 at 13:35, 1 year 2 months ago

MIRA Pharmaceuticals dévoile de nouvelles données sur le kétamir-2 lors du sommet annuel sur les thérapies contre la douleur

Ketamir-2 Données Précliniques Douleur Neuropathique MIRA Pharmaceutique Sommet Sur Les Thérapies Contre La Douleur
PRESS RELEASE

published on 09/27/2024 at 13:30, 1 year 2 months ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
MIRA Pharmaceuticals presents preclinical results at Pain Therapeutics Summit showcasing that Ketamir-2 achieves 100% reversal of neuropathic pain. The innovative therapy targets NMDA receptors for enhanced efficacy

Preclinical Results MIRA Pharmaceuticals Ketamir-2 NMDA Receptor Neuropathic Pain

Accesswire

Published on 12/05/2025 at 02:35, 8 hours 50 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 8 hours 55 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 10 hours 25 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 20 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 25 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 11 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 11:08, 16 minutes ago

Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 12/05/2025 at 10:30, 55 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 10 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 45 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration

Les Echos

Published on 12/05/2025 at 08:45, 2 hours 40 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 2 hours 40 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 2 hours 43 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 17 hours 10 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 17 hours 25 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE